A Modified Electrochemical Sensor Based on N,S-Doped Carbon Dots/Carbon Nanotube-Poly(Amidoamine) Dendrimer Hybrids for Imatinib Mesylate Determination [PDF]
Biosensors, 2023 Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully ...
Maryam Saleh Mohammadnia +3 more
doaj +3 more sources
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]
New England Journal of Medicine, 2002 BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical
George D. Demetri +20 more
openalex +2 more sources
Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects [PDF]
Clinical and Translational Science, 2022 For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na +7 more
doaj +2 more sources
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. [PDF]
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +2 more sources
Green biosynthesis of magnetic iron oxide nanoparticles using Mentha longifolia for imatinib mesylate delivery [PDF]
IET Nanobiotechnology, 2022 In this work, the rapid, facile, and eco‐friendly green process was introduced in the preparation of β‐cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of Mentha longifolia.
Bahareh Naeimipour +4 more
doaj +2 more sources
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome. [PDF]
Br J HaematolSummary The role of imatinib in PDGFRA/B‐negative hypereosinophilic syndromes (HES) is controversial because of the heterogeneity of HES and the scarcity of prospective studies. We conducted a phase II clinical trial to evaluate the efficacy of imatinib in PDGFRA/B‐negative HES. Thirty‐two patients were treated with imatinib (100–400 mg daily), and the
Kim DH +15 more
europepmc +2 more sources
Imatinib Mesylate and Gray Hair [PDF]
New England Journal of Medicine, 2002 To the Editor: The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue).1 We would like to report a new side effect of the drug.
Gabriel Étienne +2 more
openalex +3 more sources
Imatinib mesylate in chordoma [PDF]
Cancer, 2004 AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Paolo G. Casali +17 more
openalex +4 more sources
Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1 [PDF]
Clinical Case Reports, 2020 Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
Ken‐ichi Yasuda +4 more
doaj +2 more sources
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. [PDF]
PLoS ONE, 2015 Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent ...
Ali Kadivar +7 more
doaj +2 more sources